Search

Your search keyword '"Salimi T"' showing total 6 results
Start Over Author "Salimi T" Publisher elsevier b.v.
6 results on '"Salimi T"'

2. P127 - Topic: AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTING

Author

Zeidan, A., Martin, A., Costantino, H., Modi, K., Salimi, T., Washington, T., and Epstein, R.

Subjects
*MYELODYSPLASTIC syndromes, *DEMOGRAPHIC characteristics, *DECITABINE, *THERAPEUTICS
Published
2023
Full Text
View/download PDF

5. PCN333 IMPACT OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION ON DAILY LIVING: RESULTS OF A U.S. ONLINE SURVEY OF PATIENTS WITH CANCER.

Author

Epstein, R.S., Krenitsky, J., Leone-Perkins, M.L., and Salimi, T.

Subjects
*PATIENT surveys, *MYELOSUPPRESSION, *INTERNET surveys, *CANCER patients, *INSTITUTIONAL review boards, *EXTENDED families
Abstract

Limited research has been conducted to understand the real-world impact of chemotherapy-induced myelosuppression on patients' lives. Participants who self-identified as having lung, breast, or colorectal cancer, were treated with chemotherapy in the past year, and experienced >=1 episode of myelosuppression were included. Conclusions Even with the various approaches used to address chemotherapy-induced myelosuppression, patients describe a significant real-world burden that often isolates them from family and friends and renders them unable to work or perform tasks around the home. [Extracted from the article]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results